Heart and lungs in COPD. Close friends in real life - Separate in daily medical practice?

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 69, Issue 1, 2008, Pages 11-17

  Lusuardi, M ^a   Garuti, G ^a   Massobrio, M ^a   Spagnolatti, L ^a   Bendinelli, S ^a  

^a PATHOLOGY UNIT   (Italy)

Author keywords

Beta blockers; Bronchodilators; Cardiovascular disorders; Chronic obstructive pulmonary disease; Spirometry

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; OXYGEN; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BRONCHOSPASM; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; COR PULMONALE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART REHABILITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; LONG TERM CARE; MEDICAL SPECIALIST; MONOTHERAPY; MORTALITY; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT EDUCATION; PREVALENCE; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; REVIEW; RISK FACTOR; RISK REDUCTION; SELF CARE; SIDE EFFECT; SMOKING; SMOKING CESSATION; SPIROMETRY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 42549171081     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2008.406     Document Type: Review

References (38)

1. Thom T. Heart Disease and Stroke Statistics-2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-e151.
2. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683-9
3. PubMed online, accessed October 31, 2007.
4. ISTAT. Indagine multiscopo sulle famiglie. Roma, Istituto Nazionale di Statistica, 1994.
5. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257.
6. Lucioni C, Donner CF, De Benedetto F, et al. I costi della broncopneumopatia cronica ostruttiva in Italia: la fase prospettica dello studio ICE. Pharmacoeconomics Italian Research Articles 2005; 7: 119-134.
7. http://en.wikipedia.org/wiki/Comorbidity.
8. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalization and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
9. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952-1959.
10. O'Donnell DE, Hernandez P, Aaron S, et al. Canadian Thoracic Society COPD Guidelines: Summary of high-lights for family doctors. Can Respir J 2003; 10: 183-185.
11. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003; 123: 1964-1969.
12. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of ß-agonists in patients with asthma and COPD. A Meta-Analysis. Chest 2004; 125: 2309-2321.
13. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137: 715-725.
14. Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). American Heart Journal 2002; 143: 45-55.
15. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007; 49: 171-180.
16. Berger JS, Sanborn TA, Sherman W, Brown DL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 2004; 94: 649-651.
17. Sin DD, Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
18. Rabe K, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176: 532-555.
19. Travers J, Laveneziana P, Webb KA, Kesten S, O'Donnell DE. Effect of tiotropium bromide on the cardiovascular response to exercise. Respir Med 2007; 101: 2017-2.
20. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
21. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischemic heart disease and concomitant chronic obstructive pulmonary disease. Q J Med 2005; 98: 493-497.
22. Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol 2006; 47: 2554-2560.
23. Mittleman MA. Air pollution, exercise, and cardiovascular risk. N Engl J Med 2007; 357: 1147-1149.
24. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic Effects of Smoking. Chest 2007; 131: 1557-1566.
25. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
26. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-II10.
27. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
28. 10). Am J Respir Crit Care Med 2001; 164: 826-830.
29. Franz-Josef Neumann F-J. Chlamydia pneumoniae-atherosclerosis link a sound concept in search for clinical relevance. Circulation 2002; 106: 2414.
30. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
31. Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130: 640-646.
32. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356: 775-789.
33. Rutten FH, Cramer M-JM, Lammers J-WJ, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006; 8: 706-711.
34. Lusuardi M, Orlandini D. Underutilization of spirometry for the diagnosis of COPD. Chest 2008 133: 313-4.
35. Damarla M, Pinto-Plata VM, Celli BR. COPD and spirometry: CHF and 2-D Echo; the great disconnect. Chest 2004; 126: 919S.
36. 2 distinguish between ventilation and perfusion defects during exercise testing in patients with lung and heart diseases. Chest 2007; 132: 977-83.
37. American Thoracic Society. Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002; 166: 11-117.
38. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, Franklin B, Sanderson B, Southard D; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Association of Cardiovascular and Pulmonary Rehabilitation. Core components of cardiac rehabilitation/ secondary prevention programs: 2007 update. Circulation 2007; 115: 2675-2682.